About Red Reishi 9% Mushroom Extract PowderOur Red Reishi 9% delivers an unprecedented 9% ganoderic acids by HPLC, making it the highest concentration reishi supplement we’ve tested. These triterpene compounds drive the majority of reishi’s benefits for sleep, longevity, and immune support, allowing you to experience the full spectrum of reishi’s effects without consuming massive doses of lower-potency extracts.
Our Red Reishi 9% Story
We spent years searching the global market for a truly high-potency reishi extract, consistently finding products that maxed out at 2% ganoderic acids. Most reishi supplements focus on beta-glucans or total polysaccharides, but research clearly shows that ganoderic acids drive reishi’s most distinctive effects on neuroplasticity, healthy aging, and GABAergic modulation. The problem was simple: nobody was producing reishi at the potency levels needed to unlock these benefits.
Everything changed when we discovered a specialized extraction facility that had developed proprietary methods for concentrating ganoderic acids to an extraordinary 9%. We immediately recognized this as a breakthrough and invested heavily in developing accurate HPLC testing protocols to verify and maintain this unprecedented potency. Our Red Reishi 9% represents the culmination of this multi-year search, delivering ganoderic acid concentrations that were previously impossible to achieve in a commercial supplement.
Our extract stands apart not just through potency, but precision. While other companies rely on generic mushroom extracts with inconsistent active compounds, we specifically target the triterpene fraction that contains ganoderic acids A through Z. This targeted approach means you get the cognitive clarity, sleep enhancement, and cellular protection that ganoderic acids provide, without the dilution of less active compounds found in standard reishi powders.Benefits
Supports Healthy Sleep Habits & Relaxation: The ganoderic acids create GABAergic…
| Benefit | Adaptogen |
|---|




Reviews
There are no reviews yet.